Bolt Biotherapeutics (BOLT) Stock Price, News & Analysis

Company Overview

Bolt Metals Corp., an exploration company, engages in the acquisition and exploration of mineral properties in Indonesia and Canada. The company primarily explores for nickel, gold, and cobalt deposits. Its flagship project is the Cyclops project covering an area of approximately 5,000 hectares located in Papua province, Indonesia. The company was formerly known as Pacific Rim Cobalt Corp. and changed its name to Bolt Metals Corp. in February 2020. Bolt Metals Corp. is headquartered in West Vancouver, Canada.

Key Stats

• Today's Range: N/A
• 50-Day Range: N/A
• 52-Week Range: N/A
• Volume: 71,500 shs
• Average Volume: 18,200 shs
• Market Capitalization: N/A
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

BOLT Stock Analysis - Frequently Asked Questions

What other stocks do shareholders of Bolt Biotherapeutics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Bolt Biotherapeutics investors own include Associated British Foods (ABF), Chaarat Gold (CGH), Fossil Group (FOSL), AMC Entertainment (AMC), Bank of America (BAC) and

Industry, Sector and Symbol

• Stock Exchange: CNSX
• Sector: Basic Materials
• Industry: Other Industrial Metals & Mining
• Sub-Industry: N/A
• Current Symbol: CNSX:BOLT
• CIK: N/A
• Web: pacificrimcobalt.com
• Phone: 604-922-8272
• Fax: N/A
• Employees: 65
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: N/A
• Free Float: N/A
• Market Cap: N/A
• Optionable: Not Optionable
• Beta: N/A